SCHEMBL4340290

SCHEMBL4340290

CC(C)(C)[Si](C)(C)OC1CCCC2[C@@H](O)C[C@@H]3[C@H](CC[C@]4(C)[C@@H](O)CC[C@@H]34)[C@@]12C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 1/20 0.39
▸ AR P10275 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ GPBAR1 Q8TDU6 2/20 0.38
▸ SHBG P04278 1/20 0.38
▸ SERPINA6 P08185 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ CYP19A1 P11511 5/20 0.38
▸ ATP1A1 P05023 4/20 0.37
▸ ATP1B1 P05026 4/20 0.37
▸ ATP1A3 P13637 4/20 0.37
▸ ATP1B2 P14415 4/20 0.37
▸ ATP1A2 P50993 4/20 0.37
▸ ATP1B3 P54709 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7296339 1.00 ESR1 (0.39) ESR1ARESR2LMNAGPBAR1
SCHEMBL4340293 0.79 CYP19A1 (0.43) LMNAGPBAR1SHBGSERPINA6CYP1A2
SCHEMBL7297224 0.79 CYP19A1 (0.43) LMNAGPBAR1SHBGSERPINA6CYP1A2
SCHEMBL7296344 0.79 CYP19A1 (0.43) LMNAGPBAR1SHBGSERPINA6CYP1A2
SCHEMBL7296749 0.77 CYP19A1 (0.38) ESR1LMNACYP3A4CYP2C19CYP19A1
SCHEMBL2792437 0.75 PPM1D (0.31) —
SCHEMBL1115738 0.74 GPBAR1 (0.35) GPBAR1
SCHEMBL1115709 0.74 GPBAR1 (0.35) GPBAR1
SCHEMBL7288543 0.73 PPM1D (0.35) —
SCHEMBL7297663 0.72 CYP19A1 (0.54) ESR1ARESR2SHBGSERPINA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8609644-B2 Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2013-12-17 — — US disclosed
US-8536160-B2 Azaheterocyclyl derivatives of androstanes and androstenes as medicaments for cardiovascular disorders SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2013-09-17 — — US disclosed
EP-2004668-B1 AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS SIGMA TAU IND FARMACEUTI (IT) 2013-03-13 — — EP disclosed
EP-2004669-B1 AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS SIGMA TAU IND FARMACEUTI (IT) 2013-01-23 — — EP disclosed
US-20110053902-A1 AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2011-03-03 — — US disclosed
US-20090275542-A1 AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2009-11-05 — — US disclosed
EP-2004669-A1 AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) 2008-12-24 — — EP disclosed
EP-2004668-A2 AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) 2008-12-24 — — EP disclosed
WO-2007118830-A1 AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2007-10-25 — — WO disclosed
WO-2007118832-A2 AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2007-10-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053902-A1 AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS PKD1, ATP1A2, ATP1A1 ESR1 166/4885AR 93/4885ESR2 72/4885
US-20090275542-A1 AZAHETEROCYCLYL DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS ATP1A2, ATP6V1B1, ATP1A3 ESR1 250/4885AR 155/4885ESR2 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback